Literature DB >> 2995512

Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

M Ho, G Miller, R W Atchison, M K Breinig, J S Dummer, W Andiman, T E Starzl, R Eastman, B P Griffith, R L Hardesty.   

Abstract

Fourteen patients who developed B cell lymphomas or lymphoproliferative lesions after kidney, liver, heart, or heart-lung transplantation in Pittsburgh during 1981-1983 had active infection with Epstein-Barr virus (EBV) of the primary (six patients), reactivated (seven patients), or chronic (one patient) type. In transplant patients without tumors, the incidence of EBV infection was 30% (39 of 128). Only three of these patients had primary infections. Thus the frequency of active infection was significantly higher in patients with tumors, and patients with primary infections were at greater risk of developing tumors. Five of 13 tumors tested contained EBV nuclear antigen (EBNA) and nine of 11 contained EBV genomes detected by DNA-DNA hybridization with BamHI K, BamHI W, or EcoRI B cloned probes. All EBNA-positive tumors, except one, were also positive by hybridization. Only one tumor was negative for both EBNA and EBV DNA. These data suggest that EBV plays an etiologic role in the development of these lesions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995512      PMCID: PMC3154749          DOI: 10.1093/infdis/152.5.876

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.

Authors:  G Henle; W Henle
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Epstein-Barr virus-IgM antibody test in infectious mononucleosis.

Authors:  J Nikoskelainen; E Klemola; J Leikola
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

4.  Secondary fluorescent staining of virus antigens by rheumatoid factor and fluorescein-conjugated anti-IgM.

Authors:  P V Shirodaria; K B Fraser; F Stanford
Journal:  Ann Rheum Dis       Date:  1973-01       Impact factor: 19.103

5.  IgM antibodies to Epstein-Barr virus in infectious mononucleosis.

Authors:  H Schmitz; M Scherer
Journal:  Arch Gesamte Virusforsch       Date:  1972

6.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

7.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

8.  IgM antibodies specific for Epstein-Barr virus in infectious mononucleosis without heterophil antibodies.

Authors:  J Nikoskelainen; J Leikola; E Klemola
Journal:  Br Med J       Date:  1974-10-12

9.  Viral infections in renal transplant recipients.

Authors:  J A Armstrong; A S Evans; N Rao; M Ho
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  63 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

3.  B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus.

Authors:  N A Brown; C R Liu; Y F Wang; C R Garcia
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

Review 4.  Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.

Authors:  T Ooka; M de Turenne-Tessier; M C Stolzenberg
Journal:  Springer Semin Immunopathol       Date:  1991

Review 5.  Lymphoproliferative disease in organ transplant recipients.

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1991

6.  Molecular genetic analysis of lymphoid tumors arising after organ transplantation.

Authors:  J Locker; M Nalesnik
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

Review 7.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

8.  The systemic distribution of Epstein-Barr virus genomes in fatal post-transplantation lymphoproliferative disorders. An in situ hybridization study.

Authors:  P S Randhawa; R Jaffe; A J Demetris; M Nalesnik; T E Starzl; Y Y Chen; L M Weiss
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

9.  AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization.

Authors:  S J Hamilton-Dutoit; G Pallesen; M B Franzmann; J Karkov; F Black; P Skinhøj; C Pedersen
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

10.  Double-step PCR assay to quantify Epstein-Barr viral load in peripheral blood.

Authors:  Massimiliano Bergallo; Chiara Merlino; Roberta Daniele; Franca Sinesi; Mara Fumagalli; Alessandro Negro Ponzi; Rossana Cavallo
Journal:  Mol Biotechnol       Date:  2004-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.